<DOC>
	<DOCNO>NCT01253915</DOCNO>
	<brief_summary>This multi-center , double-blind , placebo-controlled , parallel group trial carbon dioxide treatment moderate severe migraine . At approximately 8 US site , approximately 450 patient meet eligibility criterion randomize active placebo 1:1 ratio ensure 400 patient treat least one moderate severe migraine study drug . Patients randomize one two treatment group provide either active placebo dispenser . All patient administer study drug 10 second nostril experience qualify headache . Patients assess pain migraine-related symptom patient diary . If patient still pain and/or symptom initial dose patient may opt take 3 dos treat headache . Each patient 's participation study may last 56 day patient treat 4 headache study drug , whichever occur first . There total 2 schedule clinic visit : - Visit 1 Screening/Randomization - Visit 2 End Study ( within 7 day patient treat his/her fourth headache end 56-day treatment period , whichever occur first )</brief_summary>
	<brief_title>The Effect Nasal Carbon Dioxide Treatment Moderate Severe Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Able read understand inform consent form voluntarily consent participate study sign IRBapproved informed consent form Males females age 18 65 year Established diagnosis migraine without aura per ICHDII ( patient diagnosis menstrual migraine eligible ) At least oneyear history migraine symptom without aura Age migraine onset le 50 year History 28 migraine attack per month 3 month prior randomization Females childbearing potential must commit use acceptable method birth control ( e.g. , oral birth control pill , intrauterine device ( IUD ) , doublebarrier method contraception ) 7 day last study drug administration . To consider childbearing potential , female must postmenopausal least 2 year surgically sterile Have less 48 hour freedom headache attack migraine Have 15 headache day per month Have migraine secondary traumatic brain injury ( TBI ) Are unable comply protocol requirement Females pregnant breastfeed and/or plan become pregnant breastfeed study participation within 7 day last study drug administration Have change usage prescription migraine prophylaxis medication within 12 week prior randomization Use antipsychotic antidepressant medication ( unless migraine prophylaxis ) within 12 week prior randomization duration study Have history alcohol drug abuse within 2 year prior randomization Have psychiatric disease may prevent patient compliance otherwise interfere ability patient participate study Have medical condition make study participation unwise opinion Investigator ( e.g. , significant COPD , heart disease , etc . ) Have concurrent diagnosis temporomandibular disorder ( TMD ) trigeminal neuralgia require treatment Clinically significant deviate septum , nasal polyp nasal condition prevents unrestricted breathing nostril Are go travel extensively airplane 56day treatment period ( e.g. , anticipated travel airplane 25 % 56day treatment period , 14 day ) Have member household also participate study Use investigational experimental therapy within 30 day randomization Have participate another study nasal CO2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>